Form 4: REGENXBIO CEO Sells 7,624 Shares Under 10b5-1 Plan

REGENXBIO Inc. CEO Curran Simpson sold 7,624 shares of common stock at a weighted average price of $10.03 per share under a Rule 10b5-1 trading plan.

Summary

• Curran Simpson, Chief Executive Officer and Director of REGENXBIO Inc. (RGNX), reported the sale of common stock.
• A total of 7,624 shares of common stock were disposed of on September 29, 2025.
• The shares were sold at a weighted average price of $10.03 per share, with individual trades ranging from $10.00 to $10.08.
• This transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following the reported transaction, Curran Simpson directly beneficially owns 236,973 shares of REGENXBIO common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sale was executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new company-specific information or a change in management's outlook.

Negatives

• The sale of shares by a Chief Executive Officer, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence by some investors, though this is mitigated by the pre-planned nature of the transaction.

Risks

• While executed under a 10b5-1 plan, insider selling could potentially be misinterpreted by the market as a signal regarding the company's future prospects, leading to short-term stock price volatility.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or competitive landscape for REGENXBIO Inc.

Stakeholder Impact

• Shareholders: May note the insider sale, but the execution under a 10b5-1 plan generally mitigates concerns about management's immediate view on the stock, as such plans are pre-scheduled.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer, or a security holder.

Key Dates

Recommendation

The sale by CEO Curran Simpson was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new company-specific information. This type of routine insider transaction, especially for a relatively small percentage of total holdings, typically does not warrant a change in investment thesis based solely on this filing. Therefore, a 'hold' recommendation is appropriate.

Keywords

REGENXBIO, RGNX, Curran Simpson, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, CEO, Director